Effect of Atorvastatin as a Renal Protection in Patients With Systemic Inflammatory Response Syndrome Using Renal Arterial Resistive Index

Renal Protection Clinical Trial

Official title:

Effect of Atorvastatin as a Renal Protection in Patients With Systemic Inflammatory Response Syndrome Using Renal Arterial Resistive Index

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT05946122
• Other study ID #: 343/ 8-2022
• Status: Recruiting
• Phase: Phase 1
• Start date: May 30, 2023
• Est. completion date: December 30, 2023

Study information

• Verified date: July 2023
• Source: Minia University
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

Offering renal protection in systemic inflammatory response syndrome by atorvastatin

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 106
• Est. completion date: December 30, 2023
• Est. primary completion date: December 12, 2023
• Accepts healthy volunteers: No
• Gender: All
• Age group: 25 Years to 70 Years

Eligibility

Inclusion Criteria:

• Patients ( male and female) with systemic inflammatory response ( total leucocytic count >12,000 mm3'. temperature >38 C, Heart rate >90 b/min and respiratory rate>20 cycle).

Exclusion Criteria:

• Hemodynamic instability

• Pre-admission chronic kidney disease.

• Intra-vascular coagulopathy

• Patients with myopathy.

Related Conditions & MeSH terms

• Renal Protection
• Systemic Inflammatory Response Syndrome

Intervention

Drug:
• Atorvastatin 40 Mg Oral Tablet
oral atorvastatin for renal protection
• placebo drug
tablet resembles atorvastatin

Locations

Country	Name	City	State
Egypt	Mina Maher Raouf	Minia	Minia University

Sponsors (1)

Lead Sponsor	Collaborator
Minia University

Country where clinical trial is conducted

Egypt, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Acute kidney injury	incidence or acute kidney injury	one week
Secondary	renal resistive vascular index	renal resistive index	one week
Secondary	APACHE score ( acute physiology and chronic health evaluation)	acute physiology and chronic health evaluation, values below 40 are considered normal while values between 41 and 71 are considered abnormal .	one week
Secondary	length of ICU stay	days of ICU admission	two weeks